DEPO - Depomed, Inc.

. Currency in USD
-
-
Stock chart is not supported by your current browser
Previous closeN/A
OpenN/A
BidN/A x N/A
AskN/A x N/A
Day's rangeN/A - N/A
52-week rangeundefined - undefined
VolumeN/A
Avg. volumeN/A
Market capN/A
Beta (3Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Associated Press4 months ago

    Depomed: 2Q Earnings Snapshot

    The Newark, California-based company said it had a loss of 33 cents per share. Earnings, adjusted for non-recurring costs and stock option expense, were 19 cents per share. The results exceeded Wall Street ...

  • Why Depomed Inc.'s Shares Soared 23.2% Higher
    Motley Fool7 months ago

    Why Depomed Inc.'s Shares Soared 23.2% Higher

    The company rewarded investors with good news today.

  • Associated Press7 months ago

    Depomed: 1Q Earnings Snapshot

    The Newark, California-based company said it had net income of 48 cents per share. Earnings, adjusted for non-recurring gains, were 28 cents per share. The results topped Wall Street expectations. The ...

  • Drug stocks dive as Trump says he's considering suing drugmakers over opioid crisis
    CNBC9 months ago

    Drug stocks dive as Trump says he's considering suing drugmakers over opioid crisis

    President Donald Trump said he's considering suing drugmakers for their role in fueling the opioid epidemic, sending pharma stocks tumbling.

  • This Biotech Flirts With Breakout Amid Battle With Opioid Makers
    Investor's Business Daily9 months ago

    This Biotech Flirts With Breakout Amid Battle With Opioid Makers

    Collegium touched a buy zone Thursday after sales of painkiller Xtampza easily beat Street expectations in the fourth quarter.

  • Exploring Depomed’s Financial Performance Today
    Market Realist9 months ago

    Exploring Depomed’s Financial Performance Today

    In fiscal 2017, Depomed (DEPO) generated total revenues of $380.7 million. Of these total revenues, $379.8 million came from product sales, and ~$844,000 came from royalties. By comparison, the company had generated total revenues of $455.8 million in fiscal 2016, of which $455 million came from product sales and $831 million from royalties.

  • Depomed versus Peers in March 2018: Analyst Ratings
    Market Realist9 months ago

    Depomed versus Peers in March 2018: Analyst Ratings

    Depomed (DEPO) is a specialty pharmaceutical company with a focus on pain and CNS (central nervous system) conditions. In March 2018, two of the seven analysts covering Depomed have given the stock a “buy” rating. By comparison, of the 22 analysts covering Merck (MRK) in March 2018, six analysts have given the stock a “strong buy” rating, and seven analysts have given it a “buy” rating, while nine analysts have given it a “hold” rating.